scholarly journals Treatments recommended by health shops for symptoms of depression

2006 ◽  
Vol 30 (10) ◽  
pp. 365-368 ◽  
Author(s):  
Joyce E. Reed ◽  
Peter Trigwell
Keyword(s):  
Hypericum Perforatum ◽  
Participant Observation ◽  
Treatment Options ◽  
Evidence Base ◽  
Symptoms Of Depression ◽  
Moderate Depression ◽  
Treatment Of Depression ◽  
Wide Range ◽  
Herbal Medicinal ◽  
Firm Evidence

Aims and MethodWe assessed the appropriateness of treatments recommended by health shop staff for symptoms of mild-to-moderate depression using participant observation with ten members of staff from ten different health shops selling herbal medicinal preparations.ResultsA wide range of treatment options were suggested by health shop staff when presented with common symptoms of depression. The majority have no firm evidence base, with the exception of St John's wort (Hypericum perforatum).Clinical ImplicationsMost alternative treatments recommended by health shops for the treatment of depression have a poor evidence base. Implications for training and communication between agencies are discussed.

Homeopathy in the 21st Century, and Comparisons with Hahnemann

Homeopathy ◽  
2021 ◽  
Author(s):  
Steven Kayne
Keyword(s):  
Health Care ◽  
Care Delivery ◽  
Treatment Options ◽  
Full Range ◽  
Evidence Base ◽  
Integrated Health Care ◽  
Positive Development ◽  
Wide Range ◽  
Integrated Health ◽  
Cast Doubt

Abstract Background Homeopathy has survived the test of time over more than 200 years and has been accepted by many consumers and practitioners across the world as being an important constituent of health care. It continues to provide successful outcomes in a wide range of conditions using traditional and newer approaches to practice and is expanding into integrated health care. This article discusses modern developments in homeopathic theory, homeopharmaceutics, homeotherapeutics, and patient access. It also considers how Hahnemann might have responded to these changes. Commentary Theoretical explanations for homeopathic mechanisms of action are complex and can involve ideas that conflict with established thinking amongst non-homeopaths. The use of different pharmacopoeial standards in the manufacture of remedies and variations in nomenclature continues to cause confusion for practitioners and patients. It also causes problems for manufacturers in providing the documentation required by national regulatory authorities to support licensing applications. Interaction with these bodies and other stakeholders is vital, to ensure the continued availability of a full range of homeopathic medicines. The incorporation of a homeopathic section within the European Pharmacopoeia (Ph. Eur.), which is used by many countries globally, is a positive development in promoting the standardisation of remedies. With increasing reliance now on evidence-based medicine, scientifically trained colleagues and sceptics have cast doubt on the validity of the observational studies that form much of the homeopathic evidence base. Recommendations The homeopathy community should engage as fully as possible in robust research to validate homeopathic practices, thus ensuring the viability of homeopathy in the future. There is an ongoing need for homeopathic practitioners to review their procedures regularly and take account of changes in patient demographics and lifestyle, and in modern methods of health care delivery. Colleagues should also be aware of patients' emerging abilities to critically assess treatment options and to judge outcomes. Future opportunities exist for homeopathy in new concepts of integrated health care that includes a range of other therapies, as well as in veterinary and environmental health. There is also the possibility of homeopathy joining social care services to improve accessibility to health care by making it available in a range of different community settings. Conclusion Hahnemann would likely have been unimpressed by the less positive contemporary influences on homeopathic practice.

Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression

2013 ◽  
Vol 12 (4) ◽  
pp. 474-486 ◽  
Author(s):  
Rosalia Crupi ◽  
Yousef Abusamra ◽  
Edoardo Spina ◽  
Gioacchino Calapai
Keyword(s):  
Hypericum Perforatum ◽  
Preclinical Data ◽  
Treatment Of Depression

scholarly journals Polymer-Drug Conjugates as Nanotheranostic Agents

2021 ◽  
Vol 2 (1) ◽  
pp. 63-81
Author(s):  
Sajana Manandhar ◽  
Erica Sjöholm ◽  
Johan Bobacka ◽  
Jessica M. Rosenholm ◽  
Kuldeep K. Bansal
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Treatment Options ◽  
The Body ◽  
Drug Conjugates ◽  
Imaging Characteristics ◽  
Wide Range ◽  
Systemic Side Effects ◽  
Theranostic Agents ◽  
The Stability

Since the last decade, the polymer-drug conjugate (PDC) approach has emerged as one of the most promising drug-delivery technologies owing to several benefits like circumventing premature drug release, offering controlled and targeted drug delivery, improving the stability, safety, and kinetics of conjugated drugs, and so forth. In recent years, PDC technology has advanced with the objective to further enhance the treatment outcomes by integrating nanotechnology and multifunctional characteristics into these systems. One such development is the ability of PDCs to act as theranostic agents, permitting simultaneous diagnosis and treatment options. Theranostic nanocarriers offer the opportunity to track the distribution of PDCs within the body and help to localize the diseased site. This characteristic is of particular interest, especially among those therapeutic approaches where external stimuli are supposed to be applied for abrupt drug release at the target site for localized delivery to avoid systemic side effects (e.g., Visudyne®). Thus, with the help of this review article, we are presenting the most recent updates in the domain of PDCs as nanotheranostic agents. Different methodologies utilized to design PDCs along with imaging characteristics and their applicability in a wide range of diseases, have been summarized in this article.

scholarly journals The Supportive Care Needs of Cancer Patients: a Systematic Review

2021 ◽  
Author(s):  
Madeleine Evans Webb ◽  
Elizabeth Murray ◽  
Zane William Younger ◽  
Henry Goodfellow ◽  
Jamie Ross
Keyword(s):  
Cancer Patients ◽  
Healthcare Professionals ◽  
Treatment Options ◽  
Complex Nature ◽  
Narrative Synthesis ◽  
Care Needs ◽  
Wide Range ◽  
Need Support ◽  
Lack Of Control ◽  
Everyday Work

AbstractCancer, and the complex nature of treatment, has a profound impact on lives of patients and their families. Subsequently, cancer patients have a wide range of needs. This study aims to identify and synthesise cancer patients’ views about areas where they need support throughout their care. A systematic  search of the literature from PsycInfo, Embase and Medline databases was conducted, and a narrative. Synthesis of results was carried out using the Corbin & Strauss “3 lines of work” framework. For each line of work, a group of key common needs were identified. For illness-work, the key needs idenitified were; understanding their illness and treatment options, knowing what to expect, communication with healthcare professionals, and staying well. In regards to everyday work, patients wanted to maintain a sense of normalcy and look after their loved ones. For biographical work, patients commonly struggled with the emotion impact of illness and a lack of control over their lives. Spiritual, sexual and financial problems were less universal. For some types of support, demographic factors influenced the level of need reported. While all patients are unique, there are a clear set of issues that are common to a majority of cancer journeys. To improve care, these needs should be prioritised by healthcare practitioners.

Cannabis use among early adolescents and transdiagnostic mental health risk factors

2021 ◽  
pp. 135910452199463
Author(s):  
Sara Moreno-Mansilla ◽  
Jorge J Ricarte ◽  
David J Hallford
Keyword(s):  
Mental Health ◽  
Risk Factors ◽  
Health Risk ◽  
Suicide Attempts ◽  
Intolerance Of Uncertainty ◽  
Cannabis Use ◽  
Health Risk Factors ◽  
Symptoms Of Depression ◽  
Modifiable Factors ◽  
Wide Range

Introduction: Cannabis is the most widely used psychoactive substance among adolescents worldwide, and the age at which consumption begins to decrease. Cannabis use in adolescents is associated with a wide range of adverse consequences in adulthood including increased vulnerability to psychosis and other mental disorders, as well as suicidal ideation and attempt. The aim of this study is to extend understanding of the link between cannabis use and mental illness by examining whether cannabis use at early ages predicts transdiagnostic variables that are precursors to severe clinical diagnoses. Methods: A descriptive cross-sectional study was conducted. The sample was made up of 605 adolescents from 7th to 9th grades, with a mean age of 13.2 years ( SD = 1.0, 47% girls). The variables evaluated were: anomalous perception of reality, intolerance of uncertainty, rumination, suicide attempt, hopelessness, and symptoms of depression and anxiety. The administration of the questionnaires was carried out in groups of 20 participants under the supervision of a researcher in a unique session of 1 hour. Results: Adolescent cannabis users scored higher on all variables assessed: anomalous perception of reality (Cohen’s d = .60), rumination ( d = .48), intolerance of uncertainty ( d = .11), suicidal attempt (affirmative answer: 25.9% of users vs 7.7% of non-users), hopelessness ( d = .85), symptoms of depression ( d = .80), and anxiety ( d = .39). A binary logistic regression showed that the only variable uniquely related to cannabis use was hopelessness (Wald = 4.560, OR: 1.159, p = .033). Conclusions: Among some mental health risk factors, hopelessness appears uniquely related to cannabis use. Adolescents may use cannabis as a coping strategy for negative thoughts and emotions, or it may be a consequence of cannabis use. Future prevention programs should focus on preventing/treating modifiable factors such as hopelessness, and delaying cannabis use in specific subgroups of adolescents who experience pathologies such as depression or suicide attempts.

scholarly journals Inflammatory Depression—Mechanisms and Non-Pharmacological Interventions

2021 ◽  
Vol 22 (4) ◽  
pp. 1640
Author(s):  
Klara Suneson ◽  
Jesper Lindahl ◽  
Simon Chamli Hårsmar ◽  
Gustav Söderberg ◽  
Daniel Lindqvist
Keyword(s):  
Low Grade ◽  
Omega 3 ◽  
Pharmacological Interventions ◽  
Exercise Interventions ◽  
Symptoms Of Depression ◽  
Symptom Profiles ◽  
Inflammatory Status ◽  
Treatment Of Depression ◽  
Specific Symptoms ◽  
Low Grade Inflammation

Treatment of depression is hampered by the failure to identify distinct symptom profiles with distinct pathophysiologies that differentially respond to distinct treatments. We posit that inflammatory depression is a meaningful depression subtype associated with specific symptoms and biological abnormalities. We review several upstream, potentially causative, mechanisms driving low-grade inflammation in this subtype of depression. We also discuss downstream mechanisms mediating the link between inflammation and symptoms of depression, including alterations in dopaminergic neurotransmission and tryptophan metabolism. Finally, we review evidence for several non-pharmacological interventions for inflammatory depression, including probiotics, omega-3 fatty acids, and physical exercise interventions. While some evidence suggests that these interventions may be efficacious in inflammatory depression, future clinical trials should consider enriching patient populations for inflammatory markers, or stratify patients by inflammatory status, to confirm or refute this hypothesis.

scholarly journals Identification and Characterization of Novel Rat Polyomavirus 2 in a Colony of X-SCID Rats by P-PIT assay

mSphere ◽  
2016 ◽  
Vol 1 (6) ◽  
Author(s):  
Lora H. Rigatti ◽  
Tuna Toptan ◽  
Joseph T. Newsome ◽  
Patrick S. Moore ◽  
Yuan Chang
Keyword(s):  
T Cell ◽  
Potential Model ◽  
Treatment Options ◽  
Pneumocystis Carinii ◽  
Preclinical Studies ◽  
Content Type ◽  
Laboratory Rats ◽  
Wide Range ◽  
Disseminated Disease ◽  
Human Polyomaviruses

ABSTRACT Although P-PIT was developed to detect diseases associated with known human polyomaviruses, the identification of a new polyomavirus in rats suggests that it may have utility as a broad-based screen for new, as well as known polyomaviruses. Our findings suggest that RatPyV2 may be a commensal infection of laboratory rats that can lead to disseminated disease in T cell immune-deficient rats. Infection of the X-SCID rats with RatPyV2 and Pneumocystis carinii is a potential model for coinfection pathogenesis and treatment options during transplant preclinical studies. Polyomaviruses (PyVs) are known to infect a wide range of vertebrates and invertebrates and are associated with a broad spectrum of diseases, including cancers, particularly in immune-suppressed hosts. A novel polyomavirus, designated rat polyomavirus 2 (RatPyV2), was identified from a breeding colony of rats having X-linked severe combined immunodeficiency. Using a human panpolyomavirus immunohistochemistry test (P-PIT), RatPyV2 was initially detected in the parotid salivary gland of a colony member. Rolling circle amplification using DNA from harderian and parotid glands identified a novel 5.1-kb polyomavirus genome closely related to human Washington University (WU) and Karolinska Institute (KI) and vole polyomaviruses but notably divergent from Rattus norvegicus PyV1 (RnorPyV1; also designated RatPyV1). Further screening showed RatPyV2 inclusion body infection in the lung epithelium and variably in other respiratory, reproductive, and glandular tissues of 12/12 (100%) rats. IMPORTANCE Although P-PIT was developed to detect diseases associated with known human polyomaviruses, the identification of a new polyomavirus in rats suggests that it may have utility as a broad-based screen for new, as well as known polyomaviruses. Our findings suggest that RatPyV2 may be a commensal infection of laboratory rats that can lead to disseminated disease in T cell immune-deficient rats. Infection of the X-SCID rats with RatPyV2 and Pneumocystis carinii is a potential model for coinfection pathogenesis and treatment options during transplant preclinical studies.

scholarly journals Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline

2006 ◽  
Vol 189 (6) ◽  
pp. 494-501 ◽  
Author(s):  
Judit Simon ◽  
Stephen Pilling ◽  
Rachel Burbeck ◽  
David Goldberg
Keyword(s):  
Combination Therapy ◽  
Decision Analysis ◽  
Secondary Care ◽  
Treatment Options ◽  
Severe Depression ◽  
Cost Effective ◽  
Current Evidence ◽  
Resource Utilisation ◽  
Moderate Depression ◽  
The Cost

BackgroundTreatment options for depression include antidepressants, psychological therapy and a combination of the two.AimsTo develop cost-effective clinical guidelines.MethodSystematic literature reviews were used to identify clinical, utility and cost data. A decision analysis was then conducted to compare the benefits and costs of antidepressants with combination therapy for moderate and severe depression in secondary care in the UK.ResultsOver the 15-month analysis period, combination therapy resulted in higher costs and an expected 0.16 increase per person in the probability of remission and no relapse compared with antidepressants. The cost per additional successfully treated patient was £4056 (95% CI 1400–18 300); the cost per quality-adjusted life year gained was £5777 (95% CI 1900–33 800) for severe depression and £14 540 (95% CI 4800–79 400) for moderate depression.ConclusionsCombination therapy is likely to be a cost-effective first-line secondary care treatment for severe depression. Its cost-effectiveness for moderate depression is more uncertain from current evidence. Targeted combination therapy could improve resource utilisation.

Abstract 316: A Potential Mechanism Involving mTOR For The Expression Of CTGF In Agonist-stimulated Adult Cardiomyocytes

2013 ◽  
Vol 113 (suppl_1) ◽  
Author(s):  
Kamala P Sundararaj ◽  
Sundaravadivel Balasubramanian ◽  
Dorea Pleasant ◽  
Dhandapani Kuppuswamy
Keyword(s):  
Mrna Expression ◽  
Wound Repair ◽  
Cardiac Fibrosis ◽  
Interstitial Fibrosis ◽  
Treatment Options ◽  
Tissue Growth ◽  
Dependent Manner ◽  
Potential Mechanism ◽  
Wall Stiffness ◽  
Wide Range

Cardiac hypertrophy ensues as a response to multiple stimuli, such as mechanical stress, neurohumoral activation, growth factors and cytokines. Connective Tissue Growth Factor (CTGF), a potent fibrogenic cytokine, regulates a wide range of biological functions including ECM deposition, wound repair, angiogenesis, migration, differentiation, survival and proliferation. While CTGF overexpression in fibroblasts has been shown to be responsible for fibrosis in various organs, controversy exists about the source of CTGF. Since interstitial fibrosis contributes to ventricular wall stiffness and impairs diastolic function, understating how key factors such as CTGF are expressed and released for the genesis of fibrosis in the hypertrophying heart is important to develop new treatment options. To this end, we explored the signaling pathway(s) involved in the phenylephrine (PE), a hypertrophic agonist, induced expression of CTGF by cardiomyocytes (CMs). Since mammalian target of rapamycin (mTOR) is reported to regulate PE-induced hypertrophic signaling, we hypothesize that mTOR plays a role in PE induced CTGF expression in CMs. To test if CMs produce CTGF, we treated adult feline CMs with phenylephrine. PE stimulated CTGF mRNA expression in a dose and time dependent manner. mTOR forms two distinct complexes, mTORC1 and mTORC2. Whereas both complexes are sensitive to a pharmacological inhibitor Torin1, only mTORC1 is sensitive to Rapamycin inhibition. Our results indicate that PE stimulated CTGF expression could be substantially enhanced by torin1 pretreatment of CMs. Moreover, shRNA mediated silencing of Rictor in CMs, one of the components of mTORC2, significantly augmented the PE induced CTGF mRNA expression. But mTORC1 inhibition using Rapamycin or activation of its downstream target S6K1 using Rapamycin resistant S6K1 adenovirus had no impact in PE -stimulated CTGF expression. The same trend was also observed in the level of secreted CTGF. In conclusion, these results strongly indicate that mTORC2 plays a repressive role in CTGF mRNA expression in adult CMs, and that the loss of such repression in PO myocardium might be a potential mechanism for the onset of cardiac fibrosis in hypertrophying myocardium.

Bilateral Nervus Intermedius Sectioning for Geniculate Neuralgia: Case Report and Operative Video

2021 ◽  
Author(s):  
Keaton Piper ◽  
Qizhi Victoria Zheng ◽  
Robert S Heller ◽  
Siviero Agazzi
Keyword(s):  
Side Effects ◽  
Microvascular Decompression ◽  
Treatment Options ◽  
Rare Condition ◽  
Contralateral Side ◽  
Wide Range ◽  
Successful Resolution ◽  
Surgical Options ◽  
Vascular Loop ◽  
Nervus Intermedius

Abstract BACKGROUND AND IMPORTANCE Geniculate neuralgia is a rare condition characterized by excruciating ear pain. Surgical options for geniculate neuralgia include microvascular decompression and sectioning of the nervus intermedius. We report herein a case of bilateral geniculate neuralgia treated by nervus intermedius sectioning without prior microvascular decompression. To our knowledge, this is the first report of this treatment strategy with a subsequent description of the side effects of bilateral nervus intermedius disruption. CLINICAL PRESENTATION A 54-yr-old woman presented with bilateral geniculate neuralgia, worse on the left, refractory to medical therapy. Surgical treatment options were reviewed, including microvascular decompression and sectioning of the nervus intermedius. She opted for left nervus intermedius sectioning. The procedure was uncomplicated and no compressive vascular loop was identified during surgery. Postoperatively, she had complete symptom resolution with no discernable side effects. Three years later, the patient developed worsening geniculate neuralgia on the contralateral side. After the discussion of treatment options, she opted again for sectioning of the contralateral nervus intermedius with successful resolution of all symptoms after surgery. Following surgery, the patient identified partial impairment of lacrimation and gustation. She continued to have functional taste of the anterior two-thirds of the tongue, lacrimation, and hearing bilaterally. CONCLUSION Bilateral sectioning of nervus intermedius may provide benefit in patients with bilateral geniculate neuralgia without egregious side effects. However, lacrimatory and gustatory alterations are a potentially significant side effect with a wide range of symptomatology.

Sign in / Sign up

Export Citation Format

Share Document